Olanzapine + Benzodiazepines

Today, I’m going to touch on the co-administration of olanzapine with benzodiazepines.

Data is controversial regarding this, but the co-administration has not been studied in depth, which is why it is not currently recommended to give both. 

What’s the FDA’s stance?

“Concomitant administration of intramuscular olanzapine along with benzodiazepines is not recommended due to the potential for excessive sedation and cardiorespiratory depression.”

This advisory came about after there were 160 adverse events and 29 fatalities associated with IM olanzapine in 2005. 


Possible side effects of co-administration: Severe hypotension, respiratory depression

Why the FDA warning?

There was a study (n=29) looking at patient fatalities involving the administration of olanzapine.

3/29 fatalities involved olanzapine monotherapy.

1/29 fatalities involved IM olanzapine + benzodiazepine dual therapy

25/29 fatalities involved IM olanzapine + PO/IM/IV benzodiazepines + many other medications

The interesting thing about the study is that 12 patients died over 24 hours after administration of the medications. So it’s difficult to determine causality. 

Some olanzapine quick facts:

  • Olanzapine is an atypical antipsychotic

  • Side effect profile includes: neuroleptic malignant syndrome, hyperglycemia, constipation, dry mouth, tachycardia, orthostatic hypotension

    • Mortalities and increased risk of cerebrovascular accidents have been linked to elderly patients with dementia

  • IM olanzapine is 5 times more potent than PO olanzapine. 

  • ½ life: 21-54 hours

  • Peak: within 15-45 minutes

Why is this conversation controversial?

Well, if you look at the data regarding co-administration < 60 minutes apart studied in 41 patients, you see that their vitals are actually fine.

**** 4 Key takeaways ****

  1. According to the European Medicines Agency, it’s likely safe to administer olanzapine and a BZD at least 60 minutes apart

  2. It’s safer to use PO agents over IM agents. Our ED pharmacy team does not recommend administering IM of both

  3. Avoid co-administration particularly in high risk groups: elderly, dementia, acute alcohol intoxication, or patients requiring polypharmacy.

  4. If you’ve already used olanzapine, and you’re looking for an additional agent, ketamine is likely a safer option.

References: 

https://www.aliem.com/combination-parenteral-olanzapine-benzodiazepines-agitation-adverse-events/ 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125121/ 

https://foamcast.org/2019/10/29/black-boxed-medications-in-the-ed-acep-2019/ 

https://meridian.allenpress.com/mhc/article/8/5/208/37281/Coadministration-of-intramuscular-olanzapine-and 


POTD: Naloxone

Today, I’ll be touching on the life-saving medication Naloxone.

Epidemiology:

In the US, there are three million people with opioid use disorder (OUD). 68K+ people died from opioid overdoses in 2020, nearly 40% higher than 2019. The deaths were primarily attributed to synthetic opioids.

Patients who have overdosed on opioids will show the classic triad of constricted pupils, decreased respiratory rates, and somnolence. You should consider naloxone administration in OUD patients with RR<8 and GCS<12.

Naloxone:

Naloxone is the antidote for opioid overdose since it is an opioid antagonist. Naloxone is available intranasally, intramuscularly, nebulized, and intravenously.

The onset of action is within 1-2 minutes, but remember that the half-life is 20-90 minutes. The half-life of the opioids are longer, so it’s recommended to observe these patients for at least 3 hours.

The first question you must ask – could this patient die from apnea? If so, you can bolus large amounts of naloxone. If the patient is somnolent but not apneic, you can titrate smaller doses at a time.

In a patient with OUD, there is a higher likelihood that you will precipitate withdrawal through the administration of naloxone. Therefore, start with lower doses of narcan for OUD patients compared to opioid-naive patients. As a side note - some of the doses below are controversial depending on the source that you’re looking at. Remember, the dosing of naloxone depends on the route.

Intranasal narcan:

  • 4mg in one nostril intranasally

  • Redose as needed

  • MMC ED Pharmacy has kits with two 4mg spray bottles

  • Available over the counter in New York

IM/IV dosing:

  • Apneic/dying patient: administer 2mg-4mg IM/IV off the bat

  • OUD patient in overdose: 0.1mg IV (0.4 mg IM) aliquots, q1-2 minutes. Consider larger doses if your patient isn’t responding appropriately. Synthetic opioids may require higher doses (sometimes up to 10mg IV.)

    • Titration: The goal is to titrate to a point of adequate ventilation and airway protection, but not necessarily full arousal. But the patient should be arousable.

  • Opioid-naive patient in overdose: 0.4mg IV/IM

Initiating a drip:

  • Because the half-life of narcan is short, you may want to consider starting a drip for patients requiring repeat doses.

  • Calculate the amount that the patient required to wake up to an appropriate level and then put them on a drip ⅔ of that per hour.

Nebulized naloxone:

  • If the drip is taking a while to set up, you can consider administering nebulized naloxone by mixing the 0.4mg vial with NS.

I would recommend having them placed on a monitor in resus with an EtCO2. If your patient develops respiratory distress, consider non-cardiogenic pulmonary edema as a side effect and get a CXR. These patients may require intubation.

EMRAP just did a piece this month about the importance of dispensing Narcan kits in the ED (as opposed to just a prescription for it, which goes largely unfilled.) This is a lifesaving medication, so I highly recommend giving a kit to every OUD patient in the ED.

https://www.emrap.org/episode/emrap20223/takehome

Last couple of pearls and tidbits:

  • Check the skin: you may find fentanyl patches which can be causing their overdose. Fentanyl patches come in doses 12mcg-100mcg/hr and require changing q72h. Just keep in mind that the effects may linger after removal.

  • Consider making push-dose naloxone. Naloxone comes in 0.4mg vials. If you mix the vial with 10cc of NS, you will be able to give 0.04mg/ml aliquots easily.

  • If there’s literally no response to the naloxone at high doses, consider alternate etiologies. Pontine stroke may be a mimic.

  • Watch the show “Dopesick” on Hulu. It follows the story of oxycodone coming to market and the Sackler family. It’s crazy.

  • You can have your own take-home Narcan kit. Just pick it up from our friendly ED pharmacists. You could save a life!

  • Also, as a reminder, Relay for Life is also an amazing service for nonfatal opioid overdoses.

References:

https://wikem.org/wiki/Naloxone

https://emcrit.org/ibcc/opioid/

https://litfl.com/naloxone/

https://www.ncbi.nlm.nih.gov/books/NBK553166/


POTD: Supratherapeutic INR

I’ve maybe had to think about this twice during residency and both times was like ??? so I figured I should at least learn a little about it.

 

Although slowly dying out in terms of popularity, some providers STILL put their patients on warfarin. One of the last conditions where warfarin is indicated over a DOAC is in the setting of a mechanical valve, which can be a clue into the patient’s past medical history if you see it on their medication list (or that their PCP is old school). And even this may change as data on DOAC’s continues to evolve. There are multiple reasons why warfarin is a very annoying drug to work with.

 

1)    Narrow therapeutic window – for most indications the target INR is between 2-3

2)    Variable dose response

3)    Multiple drug-diet and drug-drug interactions

4)    Requiring bridging therapy

 

The main benefit of warfarin is that in the event of bleeding or hemorrhage, there are easy and effective reversal agents.

 

So, what happens if you shotgun labs on a patient (as one does) and their INR returns at a higher level? Like 4? 7? 10?? It depends on the scenario.

 

Significant or Life-Threatening Bleeding – very obvious, no thought involved. Obviously do not wait for confirmatory testing before treating.

-       Stop warfarin

-       Give Vitamin K 10mg IV over 20-60min. Some considerations…

o   Vitamin K works by helping the body produce more coagulation factors (no, I won’t go over the mechanism). This takes more than a few hours and does not help immediately

o   If started on vitamin K the patient will usually be refractory to warfarin for some time, but this is less of a problem as a different (and likely better) anticoagulant can be started in the interim

-       4-factor prothrombin complex concentrate (PCC) – Kcentra (what we have at Maimonides). I think this will end up institution specific, but we do…

o   Fixed approach – does not depend on INR. After a lovely discussion with pharmacy, studies appear to show that it is just as effective but lowers cost as overall doses are lower. Preferred if you have a choice.

§  GI/ENT/life-threatening hemorrhage – 1500 IU

§  ICH – 2000 IU 

o   INR-based approach – start off with 1500 IU empirically then add SUPPLEMENTAL dose…

§  INR 2-4: total 25 IU/kg (max 2500)

§  INR 4-6: total 35 IU/kg (max 3500)

§  INR > 6: total 50 IU/kg (max 5000)

-       If no Kcentra, consider FFP (but it honestly sounds like you should never really consider FFP). Per UpToDate…

o   2U FFP. Check INR 15 min after infusion, if >1.5 give another 2IU. Repeat until INR < 1.5.

o   Consider Lasix if infusing large amounts

 

Luckily, the order set reflects this at Maimonides, and we don’t have to think about it here.

 

Not really a debate anymore, but Kcentra vs FFP? Kcentra…

-       Is more rapid and effective at correcting INR - ~30 min

-       Can be infused faster with less volume  less likely leading to fluid overload

-       Shorter preparation time

-       Does not require blood-type matching

-       FFP is cheaper though….      +1

 

For Urgent/Emergent procedures

-       Treat as above in discussion with surgeon or proceduralist

-       If it can wait, don’t need to treat as aggressively

 

Minor Bleeding (like epistaxis) – very complicated, decided by many factors and heavily decided by physician judgement. Some things to consider

-       Extent of bleeding and risk of progression

-       Previous bleeding history

-       Comorbidities (CKD, HTN)

-       Concomitant anti-platelet therapy

-       INR level

-       Thromboembolic risk of the patient (prosthetic valve, atrial fibrillation, history stroke/DVT/PE, etc.)

-       Therapy will range from holding warfarin, giving vitamin K, and treating as above

 

Now on to why I actually decided to make this POTD.

 

Asymptomatic Elevated INR – based on INR

-       INR > 10: oral vitamin K 2.5-5mg  response in 24-48 hours

o   Hold warfarin

o   No role for Kcentra or FFP

o   INR should be checked daily or every other day, repeat oral vitamin K as needed

-       INR 4.5-10

o   Hold warfarin (1-2 doses)

o   Can consider low dose oral vitamin K – 1 - 2.5mg. Again, consider SEVERAL factors

§  Risk of bleeding – older age, prior bleeding, higher INR  consider oral vitamin K

§  Risk of thrombosis

-       INR <4.5

o   Hold next dose of warfarin (or reduce dose, this is generally on the PCP though)

o   Needs more frequent INR checks in the immediate future

 

Does anyone NEED to be admitted for management of supratherapeutic INR? Likely not. Fortunately, or unfortunately, depends on our clinical judgement. Off the top of my head…

-       Consider calling PCP to ensure follow-up / PCP comfort

-       Consider risk of bleeding vs. risk thrombosis

-       Patient ability to follow up

-       The thousand other things we think about when deciding whether to admit or discharge patients

 

What about an elevated INR in a liver patient?

-       Do not treat like warfarin-induced elevated INR

-       Patients are usually at baseline PRO-THROMBOTIC from low levels of protein C and S (anticoagulation factors)

-       Nothing to really do for elevated INR in the cirrhotic patient – per UptoDate appears that most attempts to correct lead to adverse events (thrombosis, etc.)

 

TL;DR

-       Ensure proper patient follow-up for cases of asymptomatic supratherapeutic INR

-       INR > 10 – hold warfarin, consider 2.5 – 5mg oral vitamin K

-       INR 4.5-10 – hold warfarin, consider 1 – 2.5mg oral vitamin K

-       INR < 4.5 – hold a single dose and recheck INR (not in ED)

 

https://www.nuemblog.com/blog/supratherapeutic-inr

https://www.uptodate.com/contents/management-of-warfarin-associated-bleeding-or-supratherapeutic-inr#H21790898

http://www.emdocs.net/em-cases-liver-emergencies/

 

 

 ·